This inventor holds 10 USPTO granted patents and 11 published patent applications and 2 EPO patents. Top assignee: Kaohsiung Medical University. Active years: 2011-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011-2019
Title: The Innovations of Suh-Hang Hank Juo
Introduction
Suh-Hang Hank Juo is a prominent inventor based in Kaohsiung, Taiwan. He has made significant contributions to the field of medical science, particularly in the development of therapeutic compositions. With a total of 10 patents to his name, Juo's work focuses on innovative solutions for various health issues.
Latest Patents
One of Juo's latest patents is titled "MicroRNA-328 anti-sense composition and therapeutic use." This invention is directed towards anti-sense microRNA-328 in the form of oligodeoxyribonucleotides, or locked nucleic acid (LNA)-modified, and phosphorothioated (PS) bond-modified oligonucleotides. The patent also includes a pharmaceutical composition comprising the anti-sense microRNA-328 composition and a pharmaceutically acceptable carrier. Furthermore, it outlines a method for preventing or treating myopia by administering the anti-sense microRNA-328 composition, preferably through topical administration to the eyes.
Another significant patent is for a "Composition for treating atherosclerosis and a preparation method thereof." This invention discloses a composition for preventing and treating atherosclerosis, which includes a chalcone compound. The chalcone compound, bound with 2-hydroxyl in ring A and 4'-methoxy in ring B, has versatile therapeutic potentials against atherosclerosis. It acts as a PPARγ inducer, p44/42 MAPK inhibitor, and cell cycle blocker, showing no toxicity to human aortic smooth muscle cells (HASMCs). Additionally, the chalcone compound exhibits a synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β), and interleukin-6 (IL-6) induced by oxidized low-density lipoprotein (Ox-LDL).
Career Highlights
Suh-Hang Hank Juo has worked at Kaohsiung Medical University, where he has contributed to various research projects and innovations. His work has been instrumental in advancing medical treatments and understanding complex health issues.
Collaborations
Juo has collaborated with notable colleagues, including Yung-Song Wang and Edward Hsi. These
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile